CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
133 hedge funds and large institutions have $475M invested in CTI BioPharma Corp. (DE) Common Stock in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 55 increasing their positions, 33 reducing their positions, and 29 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 33
51% more call options, than puts
Call options by funds: $4.31M | Put options by funds: $2.85M
8% less funds holding
Funds holding: 145 → 133 (-12)
23% less capital invested
Capital invested by funds: $620M → $475M (-$145M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$46.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$30.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$13.4M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$8.31M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$4.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$20.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$18.5M |
| 3 |
LPC
Lion Point Capital
New York
|
-$16.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.6M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$9.41M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KAS
151
Kestra Advisory Services
Austin,
Texas
| – | -$179K | -29,850 | Closed |
|
|
GC
152
Gilbert & Cook
West Des Moines,
Iowa
| – | -$172K | -28,690 | Closed |
|
153
Axa
Paris,
France
| – | -$103K | -17,100 | Closed |
|
|
PMEF
154
Point72 Middle East FZE
Dubai,
United Arab Emirates
| – | -$93.7K | -15,594 | Closed |
|
|
SSG
155
Summit Securities Group
New York
| – | -$90K | -15,000 | Closed |
|
|
SAM
156
Shell Asset Management
The Hague,
Netherlands
| – | -$47K | -7,903 | Closed |
|
|
EI
157
Ellevest Inc
New York
| – | -$2K | -332 | Closed |
|
158
US Bancorp
Minneapolis,
Minnesota
| – | -$1.11K | -185 | Closed |
|
159
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$1K | -159 | Closed |
|
|
CAL
160
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | -$1K | -116 | Closed |
|
|
MCC
161
Money Concepts Capital
Palm Beach Gardens,
Florida
| – | -$12 | -2 | Closed |
|
CTIC Hedge Fund Activity: Q1 2023 in Review
133 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2023, worth a combined $475M — down 23% from $620M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CTIC and 17 opened new positions — a net loss of 12 holders — while 33 trimmed existing stakes and 55 added.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $46.5M. The largest seller was Millennium Management, cutting an estimated $20.2M.
- 133 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2023, down from 145 in Q4 2022.
- Funds reported $475M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2023, down 23% quarter-over-quarter.
- 17 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2023 and 29 closed out, a net change of -12 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2023 was Rubric Capital Management (New York), an estimated $46.5M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2023 was Millennium Management, an estimated $20.2M sold.
Based on aggregated 13F filings for Q1 2023.